Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR)

Historical Holders from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
LRMR on Nasdaq
Shares outstanding
85,635,017
Price per share
$3.81
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
85,510,151
Holdings value
$274,838,015
% of all portfolios
0%
Share change
+23,159,464
Value change
+$75,245,037
Average buys %
+0%
Average sells %
-0%
Number of holders
136
Price from insider filings
$3.20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Flynn James E 36% $82,495,505 30,667,474 Deerfield Management Company, L.P. 31 Jul 2025
MILLENNIUM MANAGEMENT LLC 5.8% +3.3% $16,043,858 +$4,532,710 4,966,831 +39% Millennium Management LLC 30 Sep 2025
Opaleye Management Inc. 4.8% -23% $16,029,000 +$614,605 4,110,000 +4% Opaleye Management, Inc. 29 Aug 2025
BlackRock, Inc. 4.8% -6% $5,266,227 -$318,470 3,079,665 -5.7% BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 4.1% $4,446,361 2,600,211 THE GOLDMAN SACHS GROUP, INC. 31 Mar 2025
As of 30 Sep 2025, Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) has 136 institutional shareholders filing 13F forms. They hold 85,510,151 shares of 85,635,017 outstanding shares (100%) .

Top 25 institutional shareholders own 92% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
DEERFIELD MANAGEMENT COMPANY, L.P. 36% 30,606,974 +44% 1.5% $98,860,526
RA CAPITAL MANAGEMENT, L.P. 7.1% 6,045,351 0% 0.24% $19,526,484
Blue Owl Capital Holdings LP 6.8% 5,853,040 +19% 5.9% $18,905,319
MILLENNIUM MANAGEMENT LLC 5.7% 4,896,831 +34% 0.01% $15,816,764
Opaleye Management Inc. 4.3% 3,720,867 -9.5% 1.5% $10,564,900
BlackRock, Inc. 3.9% 3,339,192 +9.8% 0% $10,785,590
RTW INVESTMENTS, LP 3.6% 3,125,000 0.12% $10,093,750
VANGUARD GROUP INC 3.6% 3,087,840 +44% 0% $9,973,723
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.2% 1,900,000 0.01% $6,137,000
Alyeska Investment Group, L.P. 2.2% 1,887,169 -9.1% 0.02% $6,095,556
Woodline Partners LP 1.9% 1,622,850 +161% 0.02% $5,241,806
GOLDMAN SACHS GROUP INC 1.8% 1,575,001 +1097% 0% $5,087,254
CITADEL ADVISORS LLC 1.7% 1,477,506 +11% 0% $4,772,344
Caption Management, LLC 1.5% 1,312,352 +90% 0.25% $4,238,897
Point72 Asset Management, L.P. 1.4% 1,223,866 0.01% $3,953,087
DAFNA Capital Management LLC 1.2% 1,027,764 +177% 0.82% $3,319,678
GEODE CAPITAL MANAGEMENT, LLC 1.2% 1,022,527 +13% 0% $3,303,366
AIGH Capital Management LLC 1.2% 1,000,000 1.1% $3,230,000
STATE STREET CORP 1% 891,869 +3.8% 0% $2,880,737
RENAISSANCE TECHNOLOGIES LLC 1% 858,642 +53% 0% $2,773,414
Verition Fund Management LLC 0.66% 567,683 0% 0.01% $1,833,616
AQR CAPITAL MANAGEMENT LLC 0.66% 562,403 +31% 0% $1,816,561
Driehaus Capital Management LLC 0.63% 535,464 0% 0.01% $1,729,549
MANGROVE PARTNERS IM, LLC 0.52% 442,236 -43% 0.11% $1,428,422
JANE STREET GROUP, LLC 0.49% 422,712 +3913% 0% $1,365,359

Institutional Holders of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 74,830 $278,198 +$55,782 $3.81 5
2025 Q3 85,510,151 $274,838,015 +$75,245,037 $3.23 136
2025 Q2 62,321,311 $180,120,860 +$7,437,019 $2.89 116
2025 Q1 60,827,153 $131,863,819 -$12,271,766 $2.15 101
2024 Q4 63,433,546 $245,489,139 -$5,895,216 $3.87 114
2024 Q3 64,329,070 $421,287,268 -$5,929,387 $6.55 122
2024 Q2 65,308,462 $473,379,717 +$12,179,948 $7.25 105
2024 Q1 63,594,662 $482,627,215 +$182,849,088 $7.59 104
2023 Q4 11,473 $52,202 $4.55 1
2023 Q3 38,745,394 $153,032,082 -$3,457,113 $3.95 63
2023 Q2 39,026,892 $120,192,442 -$3,680,276 $3.13 64
2023 Q1 38,462,442 $174,244,129 +$995,786 $4.53 68
2022 Q4 38,766,976 $160,093,910 +$976,434 $4.13 47
2022 Q3 38,478,464 $123,144,000 +$77,837,109 $3.20 49
2022 Q2 14,390,026 $28,219,000 -$2,239,611 $1.96 33
2022 Q1 15,257,103 $61,778,000 -$5,126,613 $4.05 40
2021 Q4 14,567,185 $157,169,000 +$903,281 $10.79 46
2021 Q3 14,425,478 $166,406,000 -$883,394 $11.53 50
2021 Q2 14,544,121 $142,829,000 -$4,477,669 $9.82 43
2021 Q1 14,110,495 $206,148,000 -$8,478,628 $14.61 54
2020 Q4 13,789,632 $295,230,000 +$5,240,769 $21.41 40
2020 Q3 13,625,016 $206,745,000 +$10,358,995 $15.17 37
2020 Q2 12,917,397 $165,684,000 +$165,683,742 $12.85 33